Protocol Ledger

NCT07560826 · Phase II · RECRUITING

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

Interventional Phase II clinical trial protocol NCT07560826 sponsored by Wake Forest University Health Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-31 Enrollment: 46 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07560826
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)46 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07560826
Protocol FieldVerified Registry Value
NCT IdentifierNCT07560826
Consolidated Lead SponsorWake Forest University Health Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment46 participants (ESTIMATED)
Registered Start Date2026-10-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI